Highlights
- •The response rate of LCM was 40.5% at 3 months, 40.5% at 6 months, 38.1% at 9 months, 35.7% at 12 months, 25.9% at 24 months, and 29.4% at 36 months.
- •The retention rate was 70.6% at 3 months, but then gradually declined to 34.8% at 36 months.
- •Our response rate was lower and our retention rate was higher in comparison to a previous study that observed patients over 36 months.
Abstract
Objective
To evaluate the efficacy and retention rate of lacosamide (LCM) over 36 months as
a treatment for children and adolescents with focal and generalized epilepsy based
on a retrospective study.
Methods
All patients prescribed LCM as monotherapy and add-on therapy between October 2016
and September 2019 at Jichi Children’s Medical Center Tochigi were included in the
study. The response rate, retention rate, and adverse effects were calculated.
Results
A total of 126 (female, n = 73) patients of 1.3 to 34.9 years old (median age: 12.8 years;
mean ± SD 13.2 ± 6.6 years) received LCM as monotherapy or add-on treatment for focal,
generalized, and combined focal and generalized epilepsy. The response rate was 40.5%
at 3 months, 40.5% at 6 months, 38.1% at 9 months, 35.7% at 12 months, 25.9% at 24 months,
and 29.4% at 36 months. For 34 patients who were observable for 36 months, the retention
rate was 70.6% at 3 months, but then gradually declined to 34.8% at 36 months. According
to the number of concomitant anti-seizure medications (ASMs), the retention rate was
higher in patients receiving <3 ASMs than in those receiving ≥3 ASMs at all observation
points. The most common adverse effects were somnolence in 21 patients (16.7%) and
dizziness in 5 patients (39.7%).
Conclusion
Our response rate was lower and our retention rate was higher in comparison to a previous
study that observed patients over 36 months. Further prospective studies in children
are required to confirm the response rate and retention rate in patients treated with
LCM over 36 months.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Epilepsy & BehaviorAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain.Arthritis Res Ther. 2007; 9: R14
- Lacosamide: a review of preclinical properties.CNS Drug Rev. 2007; 13: 21-42
- Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort.Epilepsia. 2016; 57: 1416-1425
- Current understanding of the mechanism of action of the antiepileptic drug lacosamide.Epilepsy Res. 2015; 110: 189-205
- Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation.J Neurosci Res. 2013; 91: 436-443
- Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study.Epilepsia. 2018; 59: 1004-1010
- Instruction manual for the ILAE 2017 operational classification of seizure types.Epilepsia. 2017; 58: 531-542
- Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 522-530
- ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 512-521
- The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting.Epilepsy Behav. 2018; 79: 130-137
- Lacosamide in pediatric and adult patients: comparison of efficacy and safety.Seizure. 2013; 22: 210-216
- Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China.Epilepsy Behav. 2021; 117107814
- Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients.Epilepsia. 2017; 58: 1749-1754
- Long-term lacosamide retention-Real-world experience at a tertiary epilepsy center in Ireland.Epilepsy Behav. 2017; 68: 141-145
- Novel medications for epilepsy.Drugs. 2011; 71: 2151-2178
- Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East.Seizure. 2020; 79: 75-79
- A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.CNS Drugs. 2010; 24: 1055-1068
- Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA.Epilepsy Behav. 2012; 23: 298-304
- Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy.Brain Develop. 2014; 36: 510-515
- Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.Eur J Paediatr Neurol. 2014; 18: 55-59
Brenner J, Majoie HJM, van Beek S, Carpay JA. The retention of lacosamide in patients with epilepsy and intellectual disability in three specialised institutions. Seizure 2017;52:123–130. Letter to the Editors.
Article info
Publication history
Published online: May 17, 2023
Accepted:
April 15,
2023
Received in revised form:
April 13,
2023
Received:
February 21,
2023
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
